Treating morning sickness in the United States - Changes in prescribing are needed

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Presently, 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the Food and Drug Administration. The use of ondansetron for nausea and vomiting in pregnancy has increased from 50,000 monthly prescriptions in 2008 to 110,000 at the end of 2013, despite unresolved issues regarding fetal safety and Food and Drug Administration warnings about serious dysrhythmias. In April 2013, the Food and Drug Administration approved the combination of doxylamine and pyridoxine, specifically for nausea and vomiting in pregnancy symptoms. Now that a safe and effective drug is available in the United States, there is no reason for women to be exposed to a drug of unproven maternal and fetal safety.

Original languageEnglish
Pages (from-to)602-606
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume211
Issue number6
DOIs
StatePublished - 1 Dec 2014
Externally publishedYes

Keywords

  • nausea and vomiting
  • ondansetron
  • pregnancy

Fingerprint

Dive into the research topics of 'Treating morning sickness in the United States - Changes in prescribing are needed'. Together they form a unique fingerprint.

Cite this